Angiotensin Converting Enzyme rs (1799752) Gene Polymorphism and Development of In-Stent Restenosis in Patients With Stable Coronary Artery Diseases in Sohag Hospital University.

Study Overview
=================
Brief Summary
-----------------
One of the most common medical approaches to the treatment of coronary artery disease (CAD) is the percutaneous coronary intervention (PCI) which became frequent due to high efﬁciency and safety of this procedure. Modern-day advances in pharmacotherapy and the device innovations over the last thirty years enhanced the benign outcomes of patients with unstable or multivessel CAD, and multiple co-morbidities, treated by PCI . In-stent restenosis (ISR) is a recognized complication following percutaneous coronary intervention in which the luminal diameter is narrowed through neointimal hyperplasia and vessel remodeling. Although rates of ISR have decreased in most recent years owing to newer generation drug-eluting stents, thinner struts, and better intravascular imaging modalities, ISR remains a prevalent dilemma that proves to be challenging to manage. Several factors have been proposed to contribute to ISR formation, including mechanical stent characteristics, technical factors during the coronary intervention, and biological aspects of drug-eluting stents .identiﬁcation of risk factors and mechanisms underlying ISR is necessary for understanding the process, the risk stratiﬁcation, and optimal treatment development. Restenosis, as a physiological response to mechanical damage, involves two mechanisms which are neointimal hyperplasia and vessel remodeling [3]. Several factors such as age, diabetes mellitus, hypertension, stenting of small coronary arteries, and ﬁnal total length of stents have been shown to be associated with an elevated risk of restenosis.

Official Title
-----------------
Angiotensin Converting Enzyme rs (1799752) Gene Polymorphism and Development of In-Stent Restenosis in Patients With Stable Coronary Artery Diseases in Sohag Hospital University.

Conditions
-----------------
Angiotensin Converting Enzyme rs (1799752) Gene Polymorphism and Development of In-Stent Restenosis in Patients With Stable Coronary Artery Diseases

Intervention / Treatment
-----------------
* Genetic: DNA extraction AND Real- time polymerase chain reaction analysis to POLYMORPHISM OF in in-stent restenosis (ISR) in CAD


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with CAD Exclusion Criteria: PATIENTS WITHOUT OTHER HEALTH PROBLEMS

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cases group<br>patients with ISR confirmed by coronary angiography | Genetic: DNA extraction AND Real- time polymerase chain reaction analysis to POLYMORPHISM OF in in-stent restenosis (ISR) in CAD<br>* Real- time polymerase chain reaction a gene polymorphism in in-stent restenosis (ISR) in CAD.<br>* Other names: genotyping of angiotensin converting enzyme in in-stent restenosis;|
| patients without restenosis non ISR group<br> | Genetic: DNA extraction AND Real- time polymerase chain reaction analysis to POLYMORPHISM OF in in-stent restenosis (ISR) in CAD<br>* Real- time polymerase chain reaction a gene polymorphism in in-stent restenosis (ISR) in CAD.<br>* Other names: genotyping of angiotensin converting enzyme in in-stent restenosis;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Angiotensin Converting Enzyme rs (1799752) gene polymorphism and Development of In-Stent Restenosis in Patients with Stable Coronary Artery Diseases | GENOTYPING of Converting Enzyme rs (1799752) gene in Development of In-Stent Restenosis in Patients with Stable Coronary Artery Diseases | 2 months |